Covid-19 Vaccines and its Adverse Events Following Immunization( AEFI)

Putri Dwi Bralianti, Femmy Nurul Akbar

Abstract


Background: The Indonesian government has begub to administer vaccines en mass and is planned in stages as an effort to prevent and control Covid-19 by immunity. To reduce the negative impact of immunization on individual health and the implementation of vaccination itself, it is best to know Covid-19 vaccines in Indonesia and their AEFI.

Objective: The purpose of this article is to discuss Covid-19 vaccines in Indonesia and their AEFI

Method: Systematic review of studies about Covid-19 vaccines that have been and will be used in Indonesia along with an overview of AEFI.

Results: There are five Covid-19 vaccines manufacturer that has been and will be used in Indonesia. The types of antigens used in the Covid-19 vaccine include a whole virus, protein subunits, and nucleic acid. 

Conclusion: Covid-19 vaccines are relatively safe and can rarely cause AEFI.


Keywords


vaccine, Covid-19, AEFI, Indonesia

Full Text:

PDF

References


Velavan, T. P., & Meyer, C. G. The COVID‐19 epidemic. Trop Med Int Health. 2020; 25(3): 278–80.

WHO. WHO coronavirus disease (COVID-19) .2020.[cited 2021 Feb 07]. Available from :https://covid19.who.int/.

Kemkes RI . Vaksinasi Covid-19 dilakukan secara bertahap. 2020.[cited 2021 Feb 07]. Available from :https://www.kemkes.go.id/article/view/20112400002/vaksinasi-covid-19-dilakukan-bertahap.html.

Satgas Covid-19. Mekanisme Pemantauan dan pelaporan KIPI.2021. [cited 2021 Feb 07].Available from :https://covid19.go.id/p/masyarakat-umum/mekanisme-pemantauan-dan-pelaporan-kipi.

Badan POM. Penerbitan Persetujuan Penggunaan Dalam Kondisi Darurat Atau Emergency Use Authorization EUA pertama untuk vaksin COVID-19.2021. [cited 2021 Feb 07].Available from :https://www.pom.go.id/new/view/more/pers/584/Penerbitan-Persetujuan-Penggunaan-Dalam-Kondisi-Darurat-Atau-Emergency-Use-Authorization--EUA--Pertama-Untuk-Vaksin-COVID-19.html.

MUI. Komisi Fatwa MUI Pusat Menetapkan Vaksin Covid-19 Produksi Sinovac Halal dan Suci. 2021.[cited 2021 Feb 07].Available from : https://mui.or.id/berita/29405/komisi-fatwa-mui-pusat-menetapkan-vaksin-covid-19-produksi-sinovac-halal-dan-suci/.

WHO. Covid-19 Vaccine Development. 2020.[cited 2021 Feb 07].Available from : https://www.who.int/docs/default-source/coronaviruse/risk-comms-updates/update45-vaccines-developement.pdf?sfvrsn=13098bfc_5 .

Gavi. There are four types of Covid-19 vaccines: here’s how they work.2020.[cited 2021 Feb 07]. Available from :https://www.gavi.org/vaccineswork/there-are-four-types-covid-19-vaccines-heres-how-they-work .

WHO. The different types of Covid-19 Vaccines. 2021.[cited 2021 Feb 07].Available from : https://www.who.int/news-room/feature-stories/detail/the-race-for-a-covid-19-vaccine-explained.

Satgas Penanganan Covid-19. Mengapa Vaksinasi Covid-19 diperlukan. 2021. [cited 2021 Feb 07].Available from :https://covid19.go.id/edukasi/masyarakat-umum/mengapa-vaksinasi-covid-19-diperlukan.

WHO. Global Vaccine Safety. 2020.[cited 2021 Feb 07].Available from :https://www.who.int/vaccine_safety/initiative/detection/AEFI/en/.

Chen RT, Rastogi SC, Mullen JR, Hayes SW, Cochi SL, Donlon JA, Wassilak SG. The Vaccine Adverse Event Reporting System (VAERS). Vaccine. 1994 ;12(6):542-50.

Kemkes RI. Dimulai Januari Berikut jumlah sasaran vaksinasi covid-19 di Indonesia. 2020.[cited 2021 Feb 07]. Available from :https://sehatnegeriku.kemkes.go.id/baca/umum/20201229/3036076/dimulai-januari-berikut-jumlah-sasaran-vaksinasi-covid-19-indonesia/.

Wu Z, Hu Y, Xu M, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet. 2021; 21: 181-92

Keech, C., Albert, G., Cho, I., Robertson, A., Reed, P., Neal, S.,et al. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. NEJM. 2020;383(24) :2320-32.

Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., et al. . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet .2021; 397(10269): 99-111.

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. NEJM. 2020 ; 383 (27): 2603-15.

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. NEJM .2020; 384(5) : 403-16.

Kemkes RI. Belum ditemukan reaksi anafilaktik dalam pelaksanaan vaksinasi covid-19.2021.[cited 2021 Feb 07].Available from : https://sehatnegeriku.kemkes.go.id/baca/rilis-media/20210124/3536845/belum-ditemukan-reaksi-anafilaktik-dalam-pelaksanaan-vaksinasi-covid-19/.

Kemkes RI. Begini progres pengembangan vaksin covid-19 tahap-3. 2021.[cited 2021 Feb 07].Available from : https://sehatnegeriku.kemkes.go.id/baca/rilis-media/20201102/4635868/begini-progres-pengembangan-vaksin-covid-19-tahap-iii/.

Permenkes No.12 tahun 2017. Penyelenggaraan Imunisasi. 2017.[cited 2021 Feb 07].Available from : https://persi.or.id/wp-content/uploads/2020/11/pmk122017.pdf.

Kemkes RI. Keamanan Vaksin Kemkes RI.2021.[cited 2021 Feb 07].Available from : http://keamananvaksin.kemkes.go.id/.




DOI: https://doi.org/10.15408/avicenna.v2i1.19832 Abstract - 0 PDF - 0

Refbacks

  • There are currently no refbacks.


Indexed By: